EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival

Oncogene

Volumn 25, Issue 5, 2006, Pages 769-780

  Xia, G ^a   Kumar, S R ^a   Stein, J P ^a   Singh, J ^a   Krasnoperov, V ^b   Zhu, S ^a   Hassanieh, L ^b   Smith, D L ^a   Buscarini, M ^a   Broek, D ^a   Quinn, D I ^a   Weaver, F A ^a   Gill, P S ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Vasgene Therapeutics Inc   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bladder cancer; Cell growth; EphB4; Receptor tyrosine kinase

Indexed keywords

EPHRIN RECEPTOR B4; PROTEIN; PROTEIN EPHB4; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EVALUATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIGAND BINDING; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; UROTHELIUM; XENOGRAFT;

BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DNA PRIMERS; HUMANS; RECEPTOR, EPHB4; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

MURINAE;

EID: 32244446198     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209108     Document Type: Article

References (42)

1. Adams RH, Wilkinson GA, Weiss C. (1999). Genes Dev 13: 295-306.
2. Andres AC, Zuercher G, Djonov V, Flueck M, Ziemiecki A. (1995). Int J Cancer 63: 288-296.
3. Battle E, Bacani J, Begthel H, Jonkeer S, Gregorieff A, van de Born M et al. (2005). Nature 435: 1126-1130.
4. Berclaz G, Andres AC, Albrecht D. (1996). Biochem Biophys Res 226: 869-875.
5. Berclaz G, Karamitopoulou E, Mazzucchelli L. (2003). Ann Oncol 14: 220-226.
6. Buscarini M, Quek ML, Gill P, Xia G, Quinn DI, Stein JP. (2005). BJU Int 95: 739-742.
7. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP et al (2004). J Clin Oncol 22: 1007-1013.
8. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. (2001). Clin Cancer Res 7: 1957-1962.
9. Cooper MJ, Haluschak JJ, Johnson D, Schwartz S, Morrison LJ, Lippa M et al. (1994). Oncol Res 6: 569-579.
10. Cutler SJ, Heney NM, Friedell GH. (1982) In: Bonney WW, Prout Jr GR (eds). Bladder Cancer, vol. 1. Williams & Wilkins: Baltimore, pp 35-46.
11. Di Fiore PP, Segatto O, Taylor WG, Aaronson SA, Pierce JH. (1990). Science 248: 79-83.
12. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC et al. (1994). N Engl J Med 331: 1259-1264.
13. Gerety SS, Wang HU, Chen ZF, Anderson DJ. (1999). Mol Cell 4: 403-413.
14. Gontero P, Banisadr S, Frea B, Brausi M. (2004). Eur Urol 46: 296-311.
15. Hara I, Miyake H, Hara S, Arakawa S, Kamidono S. (2001). J Urol 165: 1769-1772.
16. Hasson P, Egoz N, Winkler C, Volohonsky G, Jia S, Dinur T et al. (2004). Nat Genet 37: 101-105.
17. Holder N, Klein R. (1999). Development 126: 2033-2044.
18. Koss LG. (1979). Hum Pathol 10: 533-548.
19. Lawson ND, Scheer N, Pham VN, Kim CH, Chitnis AB, Campos-Ortega JA et al. (2001). Development 128: 3675-3683.
20. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I et al (1992). J Clin Oncol 10: 1066-1073.
21. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG et al. (1990). J Clin Oncol 8: 1050-1055.
22. Lutzeyer W, Rubben H, Dahm H. (1982). J Urol 127: 250-252.
23. Mao W, Luis E, Ross S, Silva J, Tan C, Crowley C et al. (2004). Cancer Res 64: 781-788.
24. Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL et al. (2003). Int J Cancer 104: 603-610.
25. Masood R, Xia G, Smith DL, Scalia P, Still JG, Tulpule A et al. (2005). Blood 105: 1310-1318.
26. Munarini N, Jager R, Abderhalden S, Zuercher G, Rohrbach V, Loercher S et al. (2002). J Cell Sci 115: 25-37.
27. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. (2004). Proc Natl Acad Sci USA 101: 5583-5588.
28. O'Leary DD, Wilkinson DG. (1999). Curr Opin Neurobiol 9: 65-73.
29. Oates AC, Lackmann M, Power MA. (1999). Mech Dev 83: 77-94.
30. Pasquale EB. (1997). Curr Opin Cell Biol 9: 608-615.
31. Rieger KM, Little AF, Swart JM, Kastrinakis WV, Fitzgerald JM, Hess DT et al. (1995). Br J Cancer 72: 683-690.
32. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S et al. (2001). J Clin Oncol 19: 666-675.
33. Steinle JJ, Meininger CJ, Forough R, Wu G, Wu MH, Granger HJ. (2002). J Biol Chem 277: 43830-43835.
34. Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE. 2001)). BMC Mol Biol 2: 15-23.
35. Sternberg CN, Calabro F, Pizzocaro G. (2001). Cancer 92: 2993-2998.
36. Takai N, Miyazaki T, Fujisawa K, Nasu K, Miyakawa I. (2001). Oncol Rep 8: 567-573.
37. Tickle C, Altabef M. (1999). Curr Opin Genet Dev 9: 455-460.
38. Vasala K, Paakko P, Turpeenniemi-Hujanen T. (2003). Urology 62: 952-957.
39. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ et al. (2000). J Clin Oncol 18: 3068-3077.
40. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D. (2003). Oncogene 22: 3361-3370.
41. Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D et al. (2005a). Clin Cancer Res 11: 4305-4315.
42. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V et al. (2005b). Cancer Res 65: 4623-4632.